Our Strategic Priorities Our strategy is designed to increase growth and improve our long-term financial performance, in support of our ambition to become the most recommended brand by life science researchers. Our strategic What we promised for What we achieved Our next strategic priorities FY 2017 priorities 1. Grow our core Continue to drive Put in place a new target Sustain antibody and reagents business market share gain for selection process and digital marketing faster than the primary antibodies increased the success of leadership market (including rabbit new product monoclonal launches. Further process Continue high value Our aim is to antibodies) improvements have focus to gain share generate above shortened lead times and market revenue Retain existing further improved the Continue validation growth from our consumers and success rates of launches initiative and raising existing consumer attract new ones by quality standards base, as well as by continuing to improve Increased the number of attracting new our digital and offline RabMAb® antibodies in our Implement next consumers experiences catalogue to over 11,000 phase of digital marketing vision Continue focus on Continued to grow our high quality products digital footprint to retain which are specific, current customers and selective and attract new ones. Our reproducible in the integrated marketing context for which our approach is driving better consumers use them conversion across multiple channels Continued to work closely with suppliers to add validation data to ensure consistent quality supply, as well as delivering improvements in quality by continuing to invest in technologies, including knockout validation of an increasing proportion of our broad recombinant antibody range 2. Establish new Continue to Increased our geographic Expand in related growth platforms strengthen our reach across China growth markets position in China Our aim is to deliver Introduced antibody pairs, Grow kits and assays enhanced value Continue to grow our RabMAb® antibodies in in line with multi-year by the addition of kits and assays SimpleStep ELISA® kits and aspiration attractive new business further used the FirePlex® platform product ranges or leveraging our to expand the kits/assays Expand the number services in either RabMAb® and range by introducing 234 of ‘Abcam Inside’ the same or FirePlex® technologies validated antibody pairs projects and adjacent segments and validated a range of framework and by extending these pairs in multiplex agreements immunoassays
Our Strategic Priorities Our strategy is designed to increase growth and improve our long-term financial performance, in support of our ambition to become the most recommended brand by life science researchers. Our strategic priorities What we promised for FY 2017 What we achieved Our next strategic priorities 1. Grow our core reagents business faster than the market Our aim is to generate above market revenue growth from our existing consumer base, as well as by attracting new consumers Continue to drive market share gain for primary antibodies (including rabbit monoclonal antibodies) Retain existing consumers and attract new ones by continuing to improve our digital and offline experiences Continue focus on high quality products which are specific, selective and reproducible in the context for which our consumers use them Put in place a new target selection process and increased the success of new product launches. Further process improvements have shortened lead times and further improved the success rates of launches Increased the number of RabMAb® antibodies in our catalogue to over 11,000 Continued to grow our digital footprint to retain current customers and attract new ones. Our integrated marketing approach is driving better conversion across multiple channels Continued to work closely with suppliers to add validation data to ensure consistent quality supply, as well as delivering improvements in quality by continuing to invest in technologies, including knockout validation of an increasing proportion of our broad recombinant antibody range Sustain antibody and digital marketing leadership Continue high value focus to gain share Continue validation initiative and raising quality standards Implement next phase of digital marketing vision 2. Establish new growth platforms Our aim is to deliver enhanced value by the addition of attractive new product ranges or services in either the same or adjacent segments and by extending Continue to strengthen our position in China Continue to grow our kits and assays business further leveraging our RabMAb® and FirePlex® technologies Increased our geographic reach across China Introduced antibody pairs, RabMAb® antibodies in SimpleStep ELISA® kits and used the FirePlex® platform to expand the kits/assays range by introducing 234 validated antibody pairs and validated a range of these pairs in multiplex immunoassays Expand in related growth markets Grow kits and assays in line with multi-year aspiration Expand the number of ‘Abcam Inside’ projects and framework agreements
Abcam-Prelims-Final-11.9.17.docx